Antioxidant supplements may accelerate melanoma spread
Antioxidants are often touted for their potential cancer-fighting abilities, but now researchers say the compounds may actually speed up the spread of the potentially deadly skin cancer melanoma, according to a new study done in mice and in cultured ...
Fox News - Fri, 09 Oct 2015 06:07

Antioxidants: helpful or harmful for melanoma?
Medical News Today - Fri, 09 Oct 2015 07:10

Antioxidants cause malignant melanoma to metastasize faster
EurekAlert (press release) - Thu, 08 Oct 2015 02:11

Antioxidants Facilitate Melanoma Metastasis
The Scientist - Wed, 07 Oct 2015 11:04

Nivolumab: Immunotherapy in Malignant Melanoma
Background: Although patients diagnosed with melanoma that is confined to the skin have a five-year survival rate of 98%, this number drops to 16% with widely metastatic disease. Melanoma rates have been steadily increasing since the 1970s, but ...
Medscape - Fri, 09 Oct 2015 09:18

Surgery May Raise Survival With Advanced Melanoma
THURSDAY, Oct. 8, 2015 (HealthDay News) -- New research suggests that for patients with melanoma that has spread to the abdomen, surgical removal of the tumor can extend survival. The study was led by Dr. Gary Deutsch, now a surgical oncologist at ...
WebMD - Thu, 08 Oct 2015 11:00

Surgery for Advance Melanoma Extends Survival
Newsmax - Thu, 08 Oct 2015 11:00

Surgery on melanoma that has spread into abdomen more than doubles patient ...
EurekAlert (press release) - Thu, 08 Oct 2015 09:33

Merck (MRK) Announces U.K. NICE Draft Recommendation for KEYTRUDA as Advanced ...
“We are pleased that the U.K. government has recognized the value of KEYTRUDA, and thank the government for its efforts to ensure that patients in the U.K. who have advanced melanoma have access to KEYTRUDA as soon as possible,” said Deepak ... - Fri, 09 Oct 2015 04:03

Eye-Catching Stocks: Ambev (NYSE:ABEV), JD.Com (NASDAQ:JD), Merck (NYSE:MRK)
wsnewspublishers - Fri, 09 Oct 2015 04:26

Training for Patients with Melanoma and Their Partners on Skin Examinations
Skin self-examination (SSE) training to aid early detection of melanoma recurrence is beneficial for patients with melanoma and their partners. The training could have additional benefits for those who report having low relationship quality because it ...
Oncology Nurse Advisor - Fri, 09 Oct 2015 12:07

What you don't know about choroidal melanoma
New Orleans—Carol Shields, MD, of Wills Eye Hospital ocular oncology service, shared her advice for what to look out for when it comes to choridal melanoma during the Plenary Session at the American Academy of Optometry meeting in New Orleans.
ModernMedicine - Thu, 08 Oct 2015 19:17

CDC: Melanoma rates doubled in 30 years
Without additional prevention efforts, melanoma incidence will continue to increase over the next 15 years, peaking at 112,000 new cases in 2030, the agency reported. By then, the annual cost of treatment for new melanoma cases likely will reach $1.6 ...
Healio - Fri, 09 Oct 2015 23:11

UK advisory panel backs KEYTRUDA for first-line treatment of melanoma
The UK's National Institute for Health and Care Excellence (NICE) issues a draft recommendation, called a Final Appraisal Determination or FAD, recommending Merck's (NYSE:MRK) KEYTRUDA (pembrolizumab) for the first-line treatment of adult patients ...
Seeking Alpha - Fri, 09 Oct 2015 05:22

Merck: KEYTRUDA Receives New Draft Recom ...
The FINANCIAL - Fri, 09 Oct 2015 04:48

NICE Believes Pembrolizumab Is Worth It in Treatment-Naïve Melanoma Patients Managed Markets Network - Fri, 09 Oct 2015 07:15

UK's NICE issues draft guidance recommending Merck's Keytruda in melanoma
The Pharma Letter (registration) - Fri, 09 Oct 2015 05:00

Merck: KEYTRUDA Receives New Draft Recommendation From NICE In Melanoma
Nasdaq - Fri, 09 Oct 2015 04:26

Melanoma drug gets NHS approval in England - Fri, 09 Oct 2015 04:03

Another NICE recommendation for melanoma drug Keytruda
European Pharmaceutical Review - Fri, 09 Oct 2015 05:56

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014